Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model
|
|
- Debra Hunter
- 5 years ago
- Views:
Transcription
1 Journal of Antimicrobial Chemotherapy (2007) 60, doi: /jac/dkm347 Advance Access publication 10 September 2007 Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model John F. Kokai-Kun*, Tanya Chanturiya and James J. Mond Biosynexus Incorporated, 9298 Gaither Rd, Gaithersburg, MD 20877, USA Received 11 April 2007; returned 5 June 2007; revised 13 August 2007; accepted 14 August 2007 Objectives: With the isolation of clinical strains of Staphylococcus aureus carrying the gene that confers vancomycin resistance, the need for novel antistaphylococcals has become more urgent. Lysostaphin, an example of such a novel therapeutic, is an endopeptidase that rapidly lyses S. aureus through proteolysis of the staphylococcal cell wall. We evaluated its efficacy as a therapeutic agent for treatment of systemic S. aureus infection in a mouse model. Methods: Mice (5 10 per group) challenged with methicillin-susceptible S. aureus developed bacteraemia and organ infections while mice challenged with methicillin-resistant S. aureus (MRSA) developed organ infections. The challenged mice received various intravenous doses of recombinant lysostaphin, administered once a day for 1 3 days when compared with treatment with oxacillin or vancomycin. Some mice also received treatment of lysostaphin combined with oxacillin or vancomycin. Following treatment, bacteraemia was determined, and mice were sacrificed and organ infection was determined. Results and conclusions: Lysostaphin administered at 5 mg/kg once a day for 3 days consistently cleared S. aureus from the blood and the organs of infected mice. Furthermore, the combination of lysostaphin and oxacillin or vancomycin demonstrated increased efficacy against MRSA over lysostaphin alone allowing the therapeutic dose of lysostaphin to be reduced to 1 mg/kg. These results demonstrate that lysostaphin is an effective treatment for eradicating S. aureus from the blood and from the organs of infected mice. Keywords: oxacillin, vancomycin, dosing regimen Introduction Staphylococcus aureus causes a wide range of infections, from skin infections to disseminated systemic infections leading to organ failure and death. 1 Vancomycin has been the antibiotic of choice for treatment of methicillin-resistant S. aureus (MRSA), but accumulating mutations in S. aureus have led to intermediate resistance to vancomycin (VISA), 2 and recently, several fully vancomycin-resistant strains of S. aureus carrying the vana gene, apparently acquired from enterococci, have been isolated. 3 This has left us with the spectre of very few effective antibiotics being available to treat S. aureus infections and with the probability that resistance to the remaining antibiotics will likely occur. Lysostaphin was discovered in 1960 and there was a flurry of early research which focused on lysostaphin as an antistaphylococcal agent The lack of available preparations of lysostaphin with consistently high specific activity and purity in the face of the ready availability of other effective antibiotics for use against S. aureus relegated lysostaphin to a laboratory reagent useful for lysis of S. aureus. The cloning of the lysostaphin gene from Staphylococcus simulans into expression systems like E. coli, 12 as well as new purification procedures 13 have led to production of highly purified recombinant lysostaphin with consistently high specific activity. The availability of recombinant lysostaphin, in the face of a vanishing list of effective antistaphylococcal agents, has generated renewed interest and research into lysostaphin as a potential antistaphylococcal agent. Mature lysostaphin is a 27 kda glycyl glycine zinc endopeptidase that cleaves the staphylococcal cell wall between the third and fourth glycine of the pentaglycine cross-bridges. 21 This enzymatic cleavage leads to destabilization of the staphylococcal cell wall, loss of osmotic equilibrium and rapid lysis of the staphylococci, often within seconds. 22 Lysostaphin is highly effective against both rapidly dividing S. aureus as well as quiescent... *Correspondence address. Tel: þ ; Fax: þ ; johnkun@biosynexus.com Present address. National Institutes of Health, Bethesda, MD, USA # The Author Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org
2 Kokai-Kun et al. cells, 4 and recently we have demonstrated that lysostaphin will also lyse staphylococci in biofilms killing both the sessile cells as well as disrupting the extracellular biofilm matrix. 19 A few early studies examined the potential of nonrecombinant lysostaphin, purified from S. simulans, as a therapy for S. aureus infection in animal models. 5,10,23 More recent studies utilized recombinant lysostaphin to study its capacity to eradicate S. aureus from non-systemic infections or colonization. 15,16,24,25 Lysostaphin treatment has also been shown to be a very effective therapeutic in a systemic disease model of endocarditis in rabbits 14,17,26,27 and neonatal sepsis in suckling rats. 20 In this study, we hypothesized that lysostaphin would also be an effective treatment for systemic S. aureus infection in a more convenient mouse model of S. aureus infection. Materials and methods Materials Recombinant mature lysostaphin was produced by fermentation in E. coli and purified to homogeneity by Avecia (Stanstead, UK) 28 under contract to Biosynexus Incorporated (Gaithersburg, MD, USA). Purified lysostaphin was formulated in ph 6.5, phosphate buffered saline buffer for storage at 2708C until used. Oxacillin and vancomycin were purchased from Sigma (St Louis, MO, USA). S. aureus strains Two representative strains of S. aureus were used in these studies, a capsule type 5 methicillin-susceptible strain, ATCC and a community acquired methicillin-resistant strain NRS123 (USA ) acquired from the Network on Antimicrobial Resistance in S. aureus ( Stocks were maintained frozen at 2708C in trypticase soy broth (BD, Sparks, MD, USA) before use in the systemic infection model. MICs of lysostaphin, oxacillin and vancomycin for these two staphylococcal strains were determined as per CLSI (formerly NCCLS) guidelines 30 as modified in the work of Kusuma and Kokai-Kun 31 as 0.016, 0.2 and 1 mg/l, respectively, for ATCC 49521, and 0.008,.16 and 1 mg/l, respectively, for NRS123. Mouse systemic infection model Challenge. All animal experiments were conducted in accordance with the guidelines of the Biosynexus Institutional Animal Care and Use Committee and the Office of Laboratory Animal Welfare, National Institutes of Health. Briefly, S. aureus was plated on tryptic soy agar plus 5% sheep blood (blood agar, Remel, Lenexa, KN, USA) from a frozen stock. Following 24 h of incubation of the agar plate, three isolated colonies were transferred to 1 ml of trypticase soy broth. The broth culture was incubated overnight (16 20 h) at 378C with shaking. Based on preliminary experiments to determine a challenge dose of S. aureus that resulted in consistent systemic infection without rapidly killing the mice (data not shown), the broth-grown bacteria were diluted to cfu/mouse in phosphate buffered saline (PBS; Cambrex, Walkersville, MD, USA). Actual S. aureus challenge titres were determined by serial 10-fold dilution and plating on blood agar. Six-week-old female CF-1 mice were used in these studies (HSD, Indianapolis, IN, USA). Mice were challenged with either strain of S. aureus in a final volume of 200 ml of PBS by intravenous tail injection. The day of challenge was designated as day 1 of the experiment. Treatment. Lysostaphin treatments (1 50 mg/kg) were given at various intervals beginning 3 h after bacterial challenge. Lysostaphin was administered by intravenous injection either once on the day of challenge or once per day for up to 3 days starting on the day of challenge and administered at 24 h intervals in 200 ml of PBS. Oxacillin (50 mg/kg) was administered intramuscularly in 100 ml of PBS four times per day with 3 h between doses, while vancomycin was administered intravenously at 15 mg/kg twice a day with 9 h between doses based on current dosing recommendations. 32 Treatments with oxacillin or vancomycin were also initiated 3 h after bacterial challenge on day 1. Recovery of bacteria. In some experiments, mice were bled at 24 h post-bacterial challenge to determine bacteraemia. Briefly, 100 ml samples of blood were drawn and mixed with 900 ml of PBS containing 500 U of heparin (Sigma), and 100 ml of this mixture was plated on blood agar. The limit of detection for bacteraemia was 100 cfu/ml of blood. Mice that survived until the end of the experiment were sacrificed on either day 4 or 6 of the experiment by CO 2 asphyxiation, and various organs were removed to determine organ infection. The whole organ was removed and placed in 900 ml of sterile PBS and then mechanically disrupted by macerating the organ with a sterile Pasteur pipette and then vortexing vigorously. Note, preliminary experiments determined that further disruption of the organ by sonication did not lead to additional recovery of bacteria (data not shown). Mechanically disrupted organs were further diluted in PBS as needed. Aliquots (100 ml) of supernatant from disrupted organs were plated on blood agar using a wide bore pipette tip to determine organ infection. The limit of detection for organ infection was 10 cfu/organ. Any S. aureus that were recovered from the organs of lysostaphin-treated mice were further tested for lysostaphin resistance by plating on tryptic soy agar (BD) þ 10 mg/ ml lysostaphin as previously described. 33 S. aureus recovered from untreated mice was used as a negative control for this determination. Growth of S. aureus on lysostaphin-containing agar at 24 h was considered to be lysostaphin-resistant S. aureus. In experiments studying neutropenic mice, mice were rendered temporarily neutropenic by intraperitoneal administration of two doses of 150 mg of a rat anti-mouse anti-gr-1 monoclonal antibody RB6-8C5 34 administered 24 h prior to and 24 h after bacterial challenge. Neutropenic mice were challenged with cfu of S. aureus due to their increased susceptibility to infection. The standard challenge dose of cfu of S. aureus was rapidly fatal to neutropenic mice (data not shown). Each animal experiment was conducted at least twice. Data presented are representative or combinations of these experiments. Statistical analysis of data The statistical significance of the differences between cfu recovered from various groups was analysed using a variance technique based on the ranks (Kruskal Wallis test). The reasons this statistical analysis was used are twofold. First, the distribution of the cfu was not normally distributed, and the non-parametric test statistic was an appropriate alternative. Second, the data were left-censored due to limits of detection, and the sample size was too small for other methods to be appropriate. By ranking the data, the values that were below the detection limit were always placed in the lowest rank thus alleviating the problems caused by data under the lower detection limit. Differences were considered significant if P
3 Lysostaphin for treatment of S. aureus infections in mice Results Treatment of systemic methicillin-susceptible S. aureus infection with lysostaphin To determine the efficacy of lysostaphin in clearing bacteraemia and organ infection, mice were challenged with methicillinsusceptible S. aureus (MSSA) and then treated with lysostaphin or oxacillin for 3 days. When control groups of mice were challenged with S. aureus ATCC 49521, all control animals developed bacteraemia by 24 h post-challenge (Figure 1). Four of ten mice treated with a single administration of 1 mg/kg lysostaphin had no detectable bacteraemia at 24 h, while no bacteraemia was detected at 24 h in any of the mice treated with a single administration of 5 mg/kg of lysostaphin. On day 6, surviving mice in each group were sacrificed and infections of the spleen, liver and kidneys were determined. Three animals in the control group had succumbed to infection prior to day 6 while the remaining seven animals were infected in the spleen, liver and kidneys (Figure 1). Control animals with.10 5 cfu recovered from the liver or kidney also consistently had visible abscesses on those organs at the time of sacrifice. Treatment with 1 mg/kg lysostaphin per day for 3 days cleared the visible organ abscesses, significantly reduced the bacterial load in all three organs and cleared some organs of infection (no cfu recovered) in some animals (Figure 1). Cfu recovered from mice treated with 5 mg/kg lysostaphin once daily for 3 days were significantly lower than from mice treated with 1 mg/kg. Lysostaphin at 5 mg/kg resulted in no detectable S. aureus in livers and kidneys and clearance of infection from the spleens of 5 of 10 of the mice (Figure 1). It should be noted that in this model, significant lung and heart infections were not detected on day 6, even in control animals. As a comparison, oxacillin, a drug used to treat MSSA infections, was also effective in this model when delivered at 50 mg/kg four times per day for 3 days, clearing S. aureus infection in four of five animals leaving one animal with an infected kidney. Two treatments of oxacillin, Figure 1. Colony forming units recovered from blood (24 h post-challenge) and organs (6 days post-challenge) of MSSA-challenged mice following 3 days of lysostaphin treatment. Mice (5 or 10 mice per group as indicated on the figure) were challenged with S. aureus ATCC and then beginning 3 h post-challenge, mice were treated with either nothing (control), lysostaphin (1 or 5 mg/kg given intravenously once per day) or oxacillin (50 mg/kg given intramuscularly four times per day) for 3 days. Twenty-four hours post-challenge (following one lysostaphin or two oxacillin treatments), mice were bled to determine bacteraemia. On the sixth day (72 h after the last treatment), the animals were sacrificed and organs were cultured for S. aureus. Note, three animals in the control group succumbed to their infections prior to day 6, so only seven symbols appear in the control group for spleen, liver and kidney. Symbols indicate cfu recovered from individual organs while horizontal lines indicate geometric means for each group. Symbols on the x-axis indicate no S. aureus were recovered from the organ. The asterisks indicate significance (P 0.05): *the result is significantly different from the control group; **the result is significantly different from the 5 mg/kg lysostaphin group. 1053
4 Kokai-Kun et al. administered 3 and 6 h post-challenge were not as effective as lysostaphin for clearance of bacteraemia however (Figure 1). In follow-up experiments, we found that lysostaphin delivered at 5 mg/kg for 2 rather than 3 days did not consistently clear S. aureus infection (data not shown). To determine if a single, high-dose infusion of lysostaphin would suffice to eradicate systemic S. aureus infection, we challenged mice with MSSA and treated with a single bolus of lysostaphin at 25 or 50 mg/kg, 3 h post-challenge. Either dose of lysostaphin cleared 100% of bacteraemia at 24 h after a single dose (data not shown). A single dose of 50 mg/kg also cleared 100% of the kidneys, 83% of the spleens and 67% of the livers of the challenged mice upon sacrifice on day 6. Reducing the treatment to a single dose of 25 mg/kg was significantly less effective than 50 mg/kg for clearance of the liver and demonstrated a trend towards being less effective in the other organs (Figure 2). Treatment of systemic MRSA infection with lysostaphin Realizing that many difficult-to-treat S. aureus infections are due to methicillin-resistant bacteria, we sought to determine the effectiveness of lysostaphin for clearing an MRSA infection caused by one of the recently emerged community-acquired MRSA strains. When CF-1 mice were challenged with cfu of NRS123 (USA400), all control animals had infected organs on day 6 (Figure 3). During the development of the mouse challenge model for this work, several MRSA strains were evaluated (data not shown). The criterion we used to select the challenge strain was that it would cause reproducible organ infection in the mice without rapidly killing the animals. Strain NRS123 was chosen as being a relevant community-acquired MRSA strain 29 and one which caused reproducible organ infection without causing the animals to succumb to infection prior to the day of sacrifice. None of the MRSA examined, including NRS123, caused detectable bacteraemia in control mice at challenge doses that were not rapidly lethal to the animals. When mice challenged with NRS123 were treated once-a-day for 3 days with 5 mg/kg lysostaphin, all 10 treated mice, sacrificed on day 6 after challenge, were cleared of S. aureus in their kidneys and had significantly reduced infections in their spleens and livers when compared with the control group (Figure 3). Reducing the lysostaphin dose to 1 mg/kg resulted in significantly reduced Figure 2. Colony forming units recovered from organs of mice 6 days post-mssa challenge following a single lysostaphin treatment. Mice (5 or 6 per group as indicated on the figure) were challenged with S. aureus ATCC and then received either nothing (control) or a single treatment of lysostaphin (25 mg/kg or 50 mg/kg given intravenously) 3 h post-challenge. On the sixth day the animals were sacrificed and organs were cultured for S. aureus. Symbols indicate cfu recovered from individual organs while horizontal lines indicate geometric means for each group. Symbols on the x-axis indicate no S. aureus were recovered from the organ. The asterisks indicate significance (P 0.05): *the result is significantly different from the control group; **the result is significantly different from the 50 mg/kg lysostaphin group. 1054
5 Lysostaphin for treatment of S. aureus infections in mice Figure 3. Colony forming units recovered from organs (6 days post-challenge) of MRSA-challenged mice following 3 days of lysostaphin treatment. Mice (5 or 10 mice per group as indicated on the figure) were challenged with S. aureus NRS123 and then beginning 3 h post-challenge, mice were treated with either nothing (control), lysostaphin (1 or 5 mg/kg given intravenously once per day), vancomycin (15 mg/kg given intravenously twice per day) or a combination of lysostaphin (1 mg/kg) plus either oxacillin (50 mg/kg given intramuscularly four times per day) or lysostaphin (1 mg/kg given intravenously once per day) plus vancomycin (15 mg/kg given intravenously twice per day) for 3 days. On the sixth day (72 h after the last treatment), the animals were sacrificed and organs were cultured for S. aureus. Symbols indicate cfu recovered from individual organs, while horizontal lines indicate geometric means for each group. Symbols on the x-axis indicate no S. aureus were recovered from the organ. The asterisks indicate significance (P 0.05): *the result is significantly different from the control group; **the result is significantly different from the 5 mg/kg lysostaphin group; ***the result is significantly different from the 1 mg/kg lysostaphin group; ****the result is significantly different from the vancomycin-only group. clearance of the spleens and kidneys of mice treated with this dose when compared with those treated with 5 mg/kg lysostaphin. Vancomycin, a drug often used to treat MRSA infections, delivered at 15 mg/kg twice a day for 3 days was also significantly less effective than 5 mg/kg lysostaphin for clearing MRSA infection of the liver and kidney (Figure 3). In vitro and in vivo synergy between lysostaphin and b-lactam antibiotics has been reported. 27,35 To determine whether such an effect could be demonstrated in our model, challenged mice were treated with 1 mg/kg lysostaphin with the addition of either oxacillin or vancomycin treatment. As shown in Figure 3, while 1 mg/kg lysostaphin significantly reduced the number of S. aureus recovered from all of the organs of the treated animals when compared with control animals, addition of 50 mg/kg oxacillin administered four times a day over the 3 days to 1 mg/kg lysostaphin treatment resulted in a significant improvement in the clearance of infection from all kidneys, spleens and livers when compared with 1 mg/kg lysostaphin alone, thus supporting in vivo synergy of b-lactams and lysostaphin even for MRSA. Oxacillin treatment alone had no effect on the course of the MRSA infection, as would be expected (data not shown). Treatment of challenged mice with a combination of 1 mg/kg lysostaphin and vancomycin also demonstrated a significantly enhanced clearance over either treatment alone for the spleens and livers, but this effect was not as dramatic as that for lysostaphin plus oxacillin (Figure 3). No lysostaphin-resistant variants were identified in experiments conducted with MRSA challenge and lysostaphin treatment. Kinetics of lysostaphin clearance of S. aureus infection To determine the time course of clearance of infection after lysostaphin treatment, we sacrificed animals 24 h after the final lysostaphin treatment (Figure 4) rather than 72 h after the final treatment as was done in the above experiments. All five mice treated with 5 mg/kg lysostaphin for 3 days and sacrificed 24 h later were heavily infected in the spleens and livers but did demonstrate a significant reduction in infection when compared 1055
6 Kokai-Kun et al. Figure 4. S. aureus recovered from organs of mice 4 days after MSSA-challenge following 3 days of lysostaphin treatment. Mice (5 mice per group, either normal or mice rendered neutropenic by treatment with an anti-neutrophil MAb, bottom right graph) were challenged with either S. aureus or S. aureus (neutropenic mice only) ATCC 49521, and then beginning 3 h post-challenge mice were treated with either nothing (control), lysostaphin (5 or 40 mg/kg given intravenously once per day), oxacillin (50 mg/kg given intramuscularly four times per day) or vancomycin (15 mg/kg given intravenously twice per day) for 3 days as indicated on the figure. On the fourth day (24 h after the last treatment), the animals were sacrificed and organs were cultured for S. aureus. Symbols indicate cfu recovered from individual organs. Horizontal lines indicate geometric means for each group. Symbols on the x-axis indicate no S. aureus recovered from the organ. The asterisks indicate significance (P 0.05): *the result is significantly different from the control group; **the result is significantly different from the 5 mg/kg lysostaphin group; ***the result is significantly different from the 40 mg/kg lysostaphin group. For the neutropenic mice (lower right graph): *the result is significantly different from the control group; **the result is significantly different from the 5 mg/kg lysostaphin group for the same organ in non-neutropenic mice. with control animals. The recovered cfu were considerably higher than those from animals treated with 5 mg/kg lysostaphin for 3 days and sacrificed 72 h later whose liver and kidneys were cleared of infection (Figure 1). Increasing the daily lysostaphin dose to 40 mg/kg given as a single dose or divided into two daily doses (data not shown) for 3 days did not have a significant impact on organ infection when compared with 5 mg/kg lysostaphin when the mice were sacrificed 24 h after the last treatment (Figure 4). Oxacillin or vancomycin treatments for 3 days were similar in their reduced effectiveness for clearance of the liver of animals that were sacrificed on day 4 when compared with 5 or 40 mg/kg lysostaphin, and significantly reduced in effectiveness for clearance of the spleen when compared with either dose of lysostaphin. Oxacillin, however, was significantly better than 5 mg/kg lysostaphin for clearance of the kidneys while vancomycin was significantly worse than 40 mg/kg lysostaphin for clearance of the kidneys (Figure 4). We considered the possibility that this finding of organ infection in lysostaphin-treated mice sacrificed 24 h after the final lysostaphin treatment may have represented the inability of lysostaphin to access bacteria that were sequestered in neutrophils. 36 To investigate this, the effects of lysostaphin in neutrophil-depleted, S. aureus infected mice sacrificed 24 h after lysostaphin treatment were examined. Neutropenic mice were more susceptible to S. aureus challenge than normal mice (data not shown), thus a lower challenge dose was required to achieve consistent infection in these mice without inducing rapid mortality. A significantly different result was seen in mice made neutropenic, challenged with S. aureus, treated with 5 mg/kg lysostaphin for 3 days and then sacrificed on day 4 (Figure 4, neutropenic mice). Unlike normal mice, neutropenic mice that were treated with lysostaphin for 3 days and then sacrificed 24 h later showed no detectable S. aureus in the kidneys of all treated animals and significantly reduced liver and spleen infections 1056
7 Lysostaphin for treatment of S. aureus infections in mice when compared with normal lysostaphin-treated mice sacrificed on day 4. This demonstrated that in the absence of neutrophils, lysostaphin is able to clear the infection more quickly than in normal mice. No lysostaphin-resistant variants were identified in experiments conducted with MSSA challenge and lysostaphin treatment. Discussion This study demonstrated that three doses of lysostaphin administered once a day at 5 mg/kg for 3 days cleared S. aureus kidney infection by MSSA and MRSA and significantly reduced spleen and liver infections in a mouse model of systemic infection (Figures 1 and 3). Lysostaphin treatment was also successful in clearing MSSA bacteraemia following a single dose of 5 mg/kg (Figure 1). At the selected challenge dose, the MRSA strain used in these studies did not cause detectable bacteraemia. These results support lysostaphin s capacity to penetrate tissue when administered intravenously inasmuch as lysostaphin treatment significantly cleared infections in various organs. Furthermore, the relatively short serum half-life of lysostaphin (previously determined to be,1h 37 ) did not appear to affect the capacity of lysostaphin to clear systemic S. aureus infection. A single intravenous injection of 50 mg/kg lysostaphin results in serum concentrations of.50 ng/ml lysostaphin for at least 5 h post-injection. 37 This concentration of lysostaphin is well above the MIC of lysostaphin for both S. aureus ATCC49521 and NRS Nonetheless, a single bolus of 25 or 50 mg/kg lysostaphin (Figure 2) appeared to be similar to or even less effective than three injections of 5 mg/kg of lysostaphin administered over 3 days (15 mg/kg total dosing) (Figure 1). We speculate that this finding suggests S. aureus in some animals was transiently sequestered from lysostaphin by 3 h postchallenge (the time of the single treatment), and thus repeated dosing over subsequent days was required to consistently clear infection as these bacteria emerged from sequestration. An alternative possibility is that only a fraction of the administered lysostaphin penetrated the infected tissue before being cleared and thus repeated dosing over 3 days may be required to achieve sufficient tissue concentrations of lysostaphin necessary to clear infection in organs of the challenged animals. Either way, these findings appear to support the use of repeated administration of lower doses of lysostaphin (5 mg/kg) over a short treatment course (3 days) rather than the use of a single large bolus treatment with lysostaphin (50 mg/kg) for treatment of S. aureus infection. Previous studies have demonstrated that there is a synergistic in vitro and in vivo effect between lysostaphin and b-lactam antibiotics, even for MRSA, 27,35 and indeed, we saw results consistent with synergy in this study (Figure 3). Addition of oxacillin to lysostaphin treatment significantly improved the effectiveness of lysostaphin allowing the effective therapeutic dose of lysostaphin to be reduced from 5 to 1 mg/kg for treatment of an MRSA infection. In addition to having the benefit of allowing a lower dose of lysostaphin to be used for treatment, adding b-lactam antibiotics would have the added benefit of preventing the possible emergence of lysostaphin-resistant S. aureus during treatment as it has been demonstrated that lysostaphin resistance and b-lactam resistance are mutually exclusive. 26,27,35 While no synergy has been demonstrated between vancomycin and lysostaphin, 14,27,35 there also appeared to be a significant additive effect between lysostaphin and vancomycin treatment in this study (Figure 3). When mice were sacrificed 24 h after the conclusion of treatment rather than 72 h after the conclusion of treatment, substantial amounts of S. aureus were recovered from the spleens and livers of lysostaphin-treated mice (Figure 4) when compared with the S. aureus recovered from the spleens and livers of lysostaphin-treated mice sacrificed 72 h after the last lysostaphin injection (Figure 1). This was the case even though mice in both experiments were treated identically for the first 3 days of the experiment. Untreated control animals were heavily infected in all organs on both days of sacrifice. Since the serum half-life of lysostaphin is,1 h, it is unlikely that this difference in recovered bacteria represents the continued antibacterial activity of lysostaphin in serum during the 48 h difference in sacrifice times. It is possible, however, that the tissue half-life of lysostaphin may be longer and thus tissue-bound lysostaphin could continue to effectively kill staphylococci during the 48 h interval between a day 4 and a day 6 sacrifice after infection; this remains to be determined. Another likely possibility is that S. aureus can survive within phagocytic cells like neutrophils, 38 but lysostaphin is unable to enter these cells. 36 Thus bacteria recovered from the spleens and livers of lysostaphin-treated mice sacrificed on day 4 of the experiment may represent S. aureus recovered from within phagocytic cells that were protected from lysostaphin activity. When lysostaphin-treated mice were sacrificed on day 6 (Figure 1), the S. aureus sequestered within the neutrophils may have already been killed by these cells thus resulting in a greater reduction of infection in all organs. Consistent with this possibility are the data presented in Figure 4, demonstrating that mice rendered neutropenic for the entire course of the experiment and then lysostaphintreated were cleared of S. aureus infection significantly more than non-neutropenic animals sacrificed on day 4. In these neutropenic mice, there were no neutrophils to shield the S. aureus from lysostaphin. The lysostaphin dosing used in these experiments is consistent with the dosing of recombinant lysostaphin used in more recent studies for the treatment of rabbit endocarditis in which lysostaphin dosage ranged from 2 to 30 mg/kg per day 14,17,26,27 and suckling rats which received 1 mg/kg lysostaphin intraperitoneally. 20 This dosing level is in contrast, however, to earlier studies using lysostaphin purified from its natural host. In those early animal studies, doses as high as 125 mg/kg lysostaphin were used to treat infected mice, 22,39 and multiple doses of.30 mg/kg lysostaphin were most effective in a dog model of endocarditis, 5 although no animals were sterilized in that study. This difference perhaps reflects the higher specific activity of recombinant lysostaphin. To date, there is only one documented case of lysostaphin being used to treat a systemic S. aureus infection in a human. 40 The present study supports the use of a short course of lysostaphin, up to 3 days, for treatment of systemic S. aureus infection. It appears that smaller doses spread over several days may be more effective in terms of total drug dose than a single larger dose of lysostaphin, and addition of oxacillin and/or vancomycin can further reduce the lysostaphin dose needed to clear infection. Determination of the actual dosing of lysostaphin in humans, however, will have to await clinical trials. 1057
8 Kokai-Kun et al. Acknowledgements We would like to thank Julio Canas and Elizabeth Mendez for excellent technical assistance and Dr Bonnie LaFleur for assistance with statistical analysis. The Network on Antimicrobial Resistance in S. aureus which is supported by a grant from the National Institute for Allergy and Infectious Diseases provided strain NRS123. Funding These studies were funded by Biosynexus Incorporated. Transparency declarations All authors are, or formerly were, employees and stock holders of Biosynexus Incorporated, and Biosynexus is in the process of developing lysostaphin for commercial use. References 1. Lowy FD. Staphylococcus aureus infection. N Engl J Med 1998; 339: Smith TL, Pearson ML, Wilcox KR et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 340: CDC. Staphylococcus aureus resistant to vancomycin-united States, MMWR 2002; 51: Crop CB, Harrison EF. The in vitro effect of lysostaphin on clinical isolates of Staphylococcus aureus. Can J Microbiol 1964; 10: Goldberg LM, DeFranco JM, Watanakunakorn C et al. Studies in experimental staphylococcal endocarditis in dogs. VI. Treatment with lysostaphin. Antimicrobial Agents Chemother (Bethesda) 1967; 7: Harris RL, Nunnery AW, Riley HD. Effect of lysostaphin on staphylococcal carriage in infants and children. Antimicrobial Agents Chemother (Bethesda) 1967; 7: Martin RR, White A. The selective activity of lysostaphin in vivo. Lab Clin Med 1967; 70: Quickel KE, Selden R, Caldwell JR et al. Efficacy and safety of topical lysostaphin treatment of persistent nasal carriage of Staphylococcus aureus. Appl Microbiol 1971; 22: Schindler CA, Schuhardt VT. Purification and properties of lysostaphin-a lytic agent for Staphylococcus aureus. Biochem Biophys Acta 1965; 97: Schuhardt VT, Schindler CA. Lysostaphin therapy in mice infected with Staphylococcus aureus. J Bacteriol 1964; 88: Zygmunt WA, Browder HP, Tavormina PA. Lytic action of lysostaphin on susceptible and resistant strains of Staphylococcus aureus. Can J Microbiol 1966; 13: Recsei PA, Gruss AD, Novick RP. Cloning, sequence and expression of the lysostaphin gene from Staphylococcus simulans. Proc Natl Acad Sci USA 1987; 84: Mierau I, Leij P, van Swam I et al. Industrial-scale production and purification of a heterologous protein in Lactococcus lactis using the nisin-controlled gene expression system NICE: the case of lysostaphin. Microb Cell Fact 2005; 4: Climo MW, Patron RL, Goldstein BP et al. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob Agents Chemother 1998; 42: Dajcs JJ, Hume EB, Moreau JM et al. Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit. Invest Opthalmol Vis Sci 2000; 41: Kokai-Kun JF, Walsh SM, Chanturiya T et al. Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob Agents Chemother 2003; 47: Patron RL, Climo MW, Goldstein BP et al. Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 1999; 43: von Eiff C, Kokai-Kun JF, Becker K et al. In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from anterior nares blood. Antimicrob Agents Chemother 2003; 47: Wu JA, Kusuma C, Mond JJ et al. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob Agents Chemother 2003; 47: Oluola O, Kong L, Fein M et al. Lysostaphin in treatment of neonatal Staphylococcus aureus infection. Antimicrob Agents Chemother 2007; 51: Schneewind OA, Fowler A, Faull KF. Structure of the cell wall anchor of surface proteins in Staphylococcus aureus. Science 1995; 268: Zygmunt WA, Tavormina PA. Lysostaphin: model for a specific enzymatic approach to infectious disease. Prog Drug Res 1972; 16: Schaffner W, Melly MA, Koenig MG. Lysostaphin: an enzymatic approach to staphylococcal disease. II. In vivo studies. Yale J Biol Med 1967; 39: Daley MJ, Oldham ER. Lysostaphin: immunogenicity of locally administered recombinant protein used in mastitis therapy. Vet Immunol Immunopath 2000; 31: Bramley AJ, Foster R. Effects of lysostaphin on Staphylococcus aureus infections of the mouse mammary gland. Res Vet Sci 1990; 49: Climo M, Ehlert K, Archer G. Mechanism and suppression of lysostaphin-resistance in oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001; 45: Kiri N, Archer G, Climo M. Combinations of lysostaphin with b-lactams are synergistic against oxacillin-resistant Staphylococcus epidermidis. Antimicrob Agents Chemother 2002; 46: McCoy M. Killing staph together: start-up Biosynexus places fermentation project in newly started Avecia facility. Chem Eng News 2004; 82: McDougal LK, Steward CD, Killgore GE et al. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol 2003; 41: National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard M7-A6. Villanova, PA, USA: NCCLS, Kusuma CM, Kokai-Kun JF. Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: Gilbert DN, Moellering RC, Sande MA. The Sandford Guide to Antimicrobial Therapy. 33rd edn. Hyde Park, VT: Antimicrobial Therapy Inc, Kusuma C, Jadanova A, Chanturiya T et al. Lysostaphinresistant variants of Staphylococcus aureus demonstrate reduced 1058
9 Lysostaphin for treatment of S. aureus infections in mice fitness in vitro and in vivo. Antimicrob Agents Chemother 2007; 51: Seung LP, Rowley DA, Dubey P et al. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci USA 1995; 92: Polack J, Latta PD, Blackburn P. In vitro activity of recombinant lysostaphin-antibiotic combinations toward methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 1993; 17: Craven N, Anderson JC. The selection in vitro of antibiotics with activity against intracellular S. aureus. J Vet Pharmacol Therap 1980; 3: Walsh S, Shah A, Mond JJ. Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol. Antimicrob Agents Chemother 2003; 47: Lowy FD. Is Staphylococcus aureus an intracellular pathogen? Trends Microbiol 2000; 8: Schaffner W, Melly MA, Hash JH et al. Lysostaphin: an enzymatic approach to staphylococcal disease. I. In vitro studies. Yale J Biol Med 1967; 39: Stark FR, Thornsvard C, Flannery EP et al. Systemic lysostaphin in man apparent antimicrobial activity in a neutropenic patient. N Engl J Med 1974; 291:
Department of Microbiology, Melaka Manipal Medical College (Manipal Campus) Manipal University, Manipal, Karnataka , India
ORIGINAL ARTICLE Volume 9 Number 4 (August 07) 08- In vitro activity of recombinant lysostaphin in combination with linezolid, vancomycin and oxacillin against methicillin-resistant Staphylococcus aureus
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationLysostaphin Treatment of Experimental Methicillin-Resistant Staphylococcus aureus Aortic Valve Endocarditis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 1998, p. 1355 1360 Vol. 42, No. 6 0066-4804/98/$04.00 0 Copyright 1998, American Society for Microbiology Lysostaphin Treatment of Experimental Methicillin-Resistant
More informationNAFCILLIN AND OXACILLIN COMPARATIVE ANTISTAPHYLOCOCCAL ACTIVITY IN MICE. J. A. YURCHENCO, M. W. HOPPER, T. D. VINCE and G. H.
46 THE JOURNAL OF ANTIBIOTICS APR. 1976 NAFCILLIN AND OXACILLIN COMPARATIVE ANTISTAPHYLOCOCCAL ACTIVITY IN MICE J. A. YURCHENCO, M. W. HOPPER, T. D. VINCE a G. H. WARREN Research Division, Wyeth Laboratories,
More informationMICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2000, p. 1062 1066 Vol. 44, No. 4 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. In Vitro Activities of Daptomycin,
More informationComparison of Clindamycin, Erythromycin, and Methicillin in Streptococcal Infections in Monkeys
ANTIbMCROBIAL AGENTS AND CHEMOTHERAPY, June 197, p. 460-465 Copyright 197 American Society for Microbiology Vol. 1, No. 6 Printed in U.S.A. Comparison of Clindamycin, Erythromycin, and Methicillin in Streptococcal
More informationLysostaphin Cream Eradicates Staphylococcus aureus Nasal Colonization in a Cotton Rat Model
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2003, p. 1589 1597 Vol. 47, No. 5 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.5.1589 1597.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationTherapy of Staphylococcal Infections in Monkeys
APuPED MICROBIOLOGY, Mar. 1971, P. 440-446 Copyright 1971 American Society for Microbiology Vol. 21, No. 3 Printed in U.S.A. Therapy of Staphylococcal Infections in Monkeys VI. Comparison of Clindamycin,
More informationDynamic Drug Combination Response on Pathogenic Mutations of Staphylococcus aureus
2011 International Conference on Biomedical Engineering and Technology IPCBEE vol.11 (2011) (2011) IACSIT Press, Singapore Dynamic Drug Combination Response on Pathogenic Mutations of Staphylococcus aureus
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationSynergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci
Journal of Antimicrobial Chemotherapy (78) 4, 53-543 Synergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci Chatrchal Watanakunakoni and Cheryl Glotzbecker Infectious
More informationVOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill
VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559 ANTIBIOTIC 6640.* Ill BIOLOGICAL STUDIES WITH ANTIBIOTIC 6640, A NEW BROAD-SPECTRUM AMINOGLYCOSIDE ANTIBIOTIC J. Allan Waitz, Eugene L. Moss, Jr., Edwin
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationMethicillin-Resistant Staphylococcus aureus
Methicillin-Resistant Staphylococcus aureus By Karla Givens Means of Transmission and Usual Reservoirs Staphylococcus aureus is part of normal flora and can be found on the skin and in the noses of one
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More informationAntimicrobial Selection to Combat Resistance
Antimicrobial Selection to Combat Resistance (Dead Bugs Don t Mutate!) Shelley C Rankin PhD Associate Professor CE Microbiology Head of Diagnostic Services & Chief of Clinical Microbiology Ryan Veterinary
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More informationProphylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi
Prophylactic antibiotic timing and dosage Dr. Sanjeev Singh AIMS, Kochi Meaning - Webster Medical Definition of prophylaxis plural pro phy lax es \-ˈlak-ˌsēz\play : measures designed to preserve health
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority
Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Healthcare Associated
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More informationAntibacterials. Recent data on linezolid and daptomycin
Antibacterials Recent data on linezolid and daptomycin Patricia Muñoz, MD. Ph.D. (pmunoz@micro.hggm.es) Hospital General Universitario Gregorio Marañón Universidad Complutense de Madrid. 1 GESITRA Reasons
More informationEvaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals
J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.
More informationSelective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016
Selective toxicity Antimicrobial Drugs Chapter 20 BIO 220 Drugs must work inside the host and harm the infective pathogens, but not the host Antibiotics are compounds produced by fungi or bacteria that
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/MRL/728/00-FINAL April 2000 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS STREPTOMYCIN AND
More informationImpact of a Standardized Protocol to Address Outbreak of Methicillin-resistant
Impact of a Standardized Protocol to Address Outbreak of Methicillin-resistant Staphylococcus Aureus Skin Infections at a large, urban County Jail System Earl J. Goldstein, MD* Gladys Hradecky, RN* Gary
More informationMRSA. ( Staphylococcus aureus; S. aureus ) ( community-associated )
005 16 190-194 ( Staphylococcus aureus; S. aureus ) ( community-associated ) ( -susceptible Staphylococcus auerus; MSSA ) ( -resistant Staphylococcus auerus; ) ( ) ( -lactam ) ( glycopeptide ) ( Staphylococcus
More informationOccurrence of Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Vancomycin in Srinagarind Hospital
Original Article Occurrence of Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Vancomycin in Srinagarind Hospital Aroonlug Lulitanond, M.Sc. 1,3 Aroonwadee Chanawong, Ph.D. 1,3
More informationConsiderations for antibiotic therapy. Christoph K. Naber Interventional Cardiology Heartcenter - Elisabeth Hospital Essen
Considerations for antibiotic therapy Christoph K. Naber Interventional Cardiology Heartcenter - Elisabeth Hospital Essen Infective Endocarditis There will never be a cure for this malignant disease! Sir
More informationAn Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus
Article ID: WMC00590 ISSN 2046-1690 An Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus Author(s):Dr. K P Ranjan, Dr. D R Arora, Dr. Neelima Ranjan Corresponding
More informationDual Antibiotic Delivery from Chitosan Sponges Prevents In Vivo Polymicrobial Biofilm Infections
Dual Antibiotic Delivery from Chitosan Sponges Prevents In Vivo Polymicrobial Biofilm Infections Ashley Parker, MS 1, James Smith, MS 1, Karen Beenken, PhD 2, Jessica Amber Jennings, PhD 3, Mark Smeltzer,
More informationPrinciples of Antimicrobial Therapy
Principles of Antimicrobial Therapy Doo Ryeon Chung, MD, PhD Professor of Medicine, Division of Infectious Diseases Director, Infection Control Office SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE CASE 1
More informationNorth West Neonatal Operational Delivery Network Working together to provide the highest standard of care for babies and families
Document Title and Reference : Guideline for the management of multi-drug resistant organisms (MDRO) Main Author (s) Simon Power Ratified by: GM NSG Date Ratified: February 2012 Review Date: March 2017
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationPrevalence & Risk Factors For MRSA. For Vets
For Vets General Information Staphylococcus aureus is a Gram-positive, aerobic commensal bacterium of humans that is carried in the anterior nares of approximately 30% of the general population. It is
More informationGuidelines for Laboratory Verification of Performance of the FilmArray BCID System
Guidelines for Laboratory Verification of Performance of the FilmArray BCID System Purpose The Clinical Laboratory Improvement Amendments (CLIA), passed in 1988, establishes quality standards for all laboratory
More informationSaxena Sonal*, Singh Trishla* and Dutta Renu* (Received for publication January 2012)
J. Commun. Dis. 44(2) 2012 : 97-102 Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus at a tertiary care hospital: Implications for clinical therapy
More informationOriginal Article. Suwanna Trakulsomboon, Ph.D., Visanu Thamlikitkul, M.D.
Original Article Vol. 25 No. 2 In vitro activity of daptomycin against MRSA:Trakulsomboon S & Thamlikitkul V. 57 In Vitro Activity of Daptomycin against Methicillin- Resistant Staphylococcus aureus (MRSA)
More informationDetection of Methicillin Resistant Strains of Staphylococcus aureus Using Phenotypic and Genotypic Methods in a Tertiary Care Hospital
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 7 (2017) pp. 4008-4014 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.607.415
More informationAntibacterial activity of Stephania suberosa extract against methicillin-resistant Staphylococcus aureus
B-O-021 Antibacterial activity of Stephania suberosa extract against methicillin-resistant Staphylococcus aureus Nongluk Autarkool *a, Yothin Teethaisong a, Sajeera Kupittayanant b, Griangsak Eumkeb a
More informationReceived 9 February 2010; returned 3 March 2010; revised 16 April 2010; accepted 18 April 2010
J Antimicrob Chemother ; 65: 7 7 doi:.9/jac/dkq59 Advance Access publication 9 June Intracellular activity of the peptide antibiotic NZ: studies with Staphylococcus aureus and human THP- monocytes, and
More informationBrief reports. Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae
Journal of Antimicrobial Chemotherapy (1997) 40, 105 108 Brief reports JAC Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae Andreas Pikis a *, Jacob A. Donkersloot
More informationAntibiotic Susceptibility of Pseudomonas aeruginosa
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 1978, p. 979-984 0066-4804/78/0013-0979$02.00/0 Copyright ) 1978 American Society for Microbiology Vol. 13, No. 6 Printed in U.S.A. Effect of Triethylenetetramine
More informationPatients. Excludes paediatrics, neonates.
Full title of guideline Author Division & Speciality Scope Gentamicin Prescribing Guideline For Adult Patients Annette Clarkson, Specialist Clinical Pharmacist Antimicrobials and Infection Control All
More informationAuthor - Dr. Josie Traub-Dargatz
Author - Dr. Josie Traub-Dargatz Dr. Josie Traub-Dargatz is a professor of equine medicine at Colorado State University (CSU) College of Veterinary Medicine and Biomedical Sciences. She began her veterinary
More informationName(s): Period: Date:
Evolution in Action: Antibiotic Resistance HASPI Medical Biology Lab 21 Background/Introduction Evolution and Natural Selection Evolution is one of the driving factors in biology. It is simply the concept
More informationEDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update
EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain
More informationBuilding a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy
Building a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy Leonardo Pagani MD Director Unit for Hospital Antimicrobial Chemotherapy
More informationBBL CHROMagar MRSA Rev. 05 October 2008
I II III IV V VI VII BBL CHROMagar MRSA 8012632 Rev. 05 October 2008 QUALITY CONTROL PROCEDURES INTRODUCTION BBL CHROMagar MRSA, supplemented with chromogens and inhibitory agents, is used for the qualitative
More informationDetection of inducible clindamycin resistance among clinical isolates of Staphylococcus aureus in a tertiary care hospital
ISSN: 2319-7706 Volume 3 Number 9 (2014) pp. 689-694 http://www.ijcmas.com Original Research Article Detection of inducible clindamycin resistance among clinical isolates of Staphylococcus aureus in a
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationAntimicrobial Resistance Acquisition of Foreign DNA
Antimicrobial Resistance Acquisition of Foreign DNA Levy, Scientific American Horizontal gene transfer is common, even between Gram positive and negative bacteria Plasmid - transfer of single or multiple
More informationA Norazah, M D*, V K E Lim, FRCPath**, MY Rohani, MPath*, A G M Kamel, MD**,
I ORIGINAL ARTICLE In-Vitro Activity of Quinupristin/ Dalfopristin, Levofloxacin and Moxifloxacin Against Fusidic Acid and Rifampicin-Resistant Strains of Methicillin Resistant Staphylococcus Aureus (MRSA)
More informationConsequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationMID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance
Antimicrobial Resistance Molecular Genetics of Antimicrobial Resistance Micro evolutionary change - point mutations Beta-lactamase mutation extends spectrum of the enzyme rpob gene (RNA polymerase) mutation
More informationComparison of Efficacies of Oral Levofloxacin and Oral Ciprofloxacin in a Rabbit Model of a Staphylococcal Abscess
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1999, p. 667 671 Vol. 43, No. 3 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Comparison of Efficacies of Oral
More informationBrief Report THE DEVELOPMENT OF VANCOMYCIN RESISTANCE IN A PATIENT WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTION
Brief Report THE DEVELOPMENT OF VANCOMYCIN RESISTANCE IN A PATIENT WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTION KRZYSZTOF SIERADZKI, PH.D., RICHARD B. ROBERTS, M.D., STUART W. HABER, M.D.,
More informationPharmacology Week 6 ANTIMICROBIAL AGENTS
Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe
More informationEffects of Minocycline and Other Antibiotics on Fusobacterium necrophorum Infections in Mice
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1975, p. 421-425 Copyright 0 1975 American Society for Microbiology Vol. 7, No. 4 Printed in U.S.A. Effects of Minocycline and Other s on Fusobacterium necrophorum
More informationTest Method Modified Association of Analytical Communities Test Method Modified Germicidal Spray Products as Disinfectants
Study Title Antibacterial Activity and Efficacy of E-Mist Innovations' Electrostatic Sprayer Product with Multiple Disinfectants Method Modified Association of Analytical Communities Method 961.02 Modified
More informationCentral Nervous System Infections
Central Nervous System Infections Meningitis Treatment Bacterial meningitis is a MEDICAL EMERGENCY. ANTIBIOTICS SHOULD BE STARTED AS SOON AS THE POSSIBILITY OF BACTERIAL MENINGITIS BECOMES EVIDENT, IDEALLY
More informationETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections
ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.
More informationThe Impact of meca Gene Testing and Infectious Diseases Pharmacists. Intervention on the Time to Optimal Antimicrobial Therapy for ACCEPTED
JCM Accepts, published online ahead of print on 7 May 2008 J. Clin. Microbiol. doi:10.1128/jcm.00801-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationPharmacological Evaluation of Amikacin in Neonates
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1975, p. 86-90 Copyright 0 1975 American Society for Microbiology Vol. 8, No. 1 Printed in U.SA. Pharmacological Evaluation of Amikacin in Neonates JORGE B.
More informationMRSA surveillance 2014: Poultry
Vicky Jasson MRSA surveillance 2014: Poultry 1. Introduction In the framework of the FASFC surveillance, a surveillance of MRSA in poultry has been executed in order to determine the prevalence and diversity
More information1 Beth Israel Deaconess Medical Center, Boston, MA, US. 2 J&P MEDICAL RESEARCH LTD., Vienna, Austria and
AAC Accepts, published online ahead of print on 23 November 2009 Antimicrob. Agents Chemother. doi:10.1128/aac.00348-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE
European Medicines Agency Veterinary Medicines and Inspections EMEA/CVMP/211249/2005-FINAL July 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE DIHYDROSTREPTOMYCIN (Extrapolation to all ruminants)
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationExploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent
Supplementary materials Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent Shankar Thangamani 1, Haroon Mohammad 1, Mostafa Abushahba 1, Maha Hamed 1, Tiago Sobreira
More informationEvaluation of MicroScan MIC Panels for Detection of
JOURNAL OF CLINICAL MICROBIOLOGY, May 1988, p. 816-820 Vol. 26, No. 5 0095-1137/88/050816-05$02.00/0 Copyright 1988, American Society for Microbiology Evaluation of MicroScan MIC Panels for Detection of
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amfipen LA 100 mg/ml suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Each ml contains:
More informationRESISTANCE OF STAPHYLOCOCCUS AUREUS TO VANCOMYCIN IN ZARQA, JORDAN
RESISTANCE OF STAPHYLOCOCCUS AUREUS TO VANCOMYCIN IN ZARQA, JORDAN Hussein Azzam Bataineh 1 ABSTRACT Background: Vancomycin has been widely used in the treatment of infections caused by Methicillin-Resistant
More informationMorphological and Biochemical Alterations in Staphylococcus epidermidis Stepwise Adapted to Vancomycin Resistance
VANCOMYCIN RESISTANCE IN STAPHYLOCOCCUS EPIDERMIDIS Morphological and Biochemical Alterations in Staphylococcus epidermidis Stepwise Adapted to Vancomycin Resistance 1 Marvita D. McGuire and Robert S.
More informationPrinciples of Anti-Microbial Therapy Assistant Professor Naza M. Ali. Lec 1
Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali Lec 1 28 Oct 2018 References Lippincott s IIIustrated Reviews / Pharmacology 6 th Edition Katzung and Trevor s Pharmacology / Examination
More informationDevelopment of Resistant Bacteria Isolated from Dogs with Otitis Externa or Urinary Tract Infections after Exposure to Enrofloxacin In Vitro
A. M. Brothers, P. S. Gibbs, and R. E. Wooley Development of Resistant Bacteria Isolated from Dogs with Otitis Externa or Urinary Tract Infections after Exposure to Enrofloxacin In Vitro Amy M. Brothers,
More informationPrinciples of Antimicrobial therapy
Principles of Antimicrobial therapy Laith Mohammed Abbas Al-Huseini M.B.Ch.B., M.Sc, M.Res, Ph.D Department of Pharmacology and Therapeutics Antimicrobial agents are chemical substances that can kill or
More informationThe Disinfecting Effect of Electrolyzed Water Produced by GEN-X-3. Laboratory of Diagnostic Medicine, College of Medicine, Soonchunhyang University
The Disinfecting Effect of Electrolyzed Water Produced by GEN-X-3 Laboratory of Diagnostic Medicine, College of Medicine, Soonchunhyang University Tae-yoon Choi ABSTRACT BACKGROUND: The use of disinfectants
More informationIsolation of antibiotic producing Actinomycetes from soil of Kathmandu valley and assessment of their antimicrobial activities
International Journal of Microbiology and Allied Sciences (IJOMAS) ISSN: 2382-5537 May 2016, 2(4):22-26 IJOMAS, 2016 Research Article Page: 22-26 Isolation of antibiotic producing Actinomycetes from soil
More informationETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae
ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;
More informationAntibiotics. Antimicrobial Drugs. Alexander Fleming 10/18/2017
Antibiotics Antimicrobial Drugs Chapter 20 BIO 220 Antibiotics are compounds produced by fungi or bacteria that inhibit or kill competing microbial species Antimicrobial drugs must display selective toxicity,
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationLe infezioni di cute e tessuti molli
Le infezioni di cute e tessuti molli SCELTE e STRATEGIE TERAPEUTICHE Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Treatment of complicated skin and skin structure infections
More informationTitle: N-Acetylcysteine (NAC) Mediated Modulation of Bacterial Antibiotic
AAC Accepts, published online ahead of print on June 00 Antimicrob. Agents Chemother. doi:0./aac.0070-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationUSA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION
VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS
More informationJournal of Antimicrobial Chemotherapy Advance Access published August 26, 2006
Journal of Antimicrobial Chemotherapy Advance Access published August, Journal of Antimicrobial Chemotherapy doi:./jac/dkl Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae,
More informationComparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys. Géza Sárközy
Comparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys Géza Sárközy Department of Pharmacology and Toxicology Faculty of Veterinary Science Szent István University
More informationSignificant human pathogen. SSTI Biomaterial related infections Osteomyelitis Endocarditis Toxin mediated diseases TSST Staphylococcal enterotoxins
Staphylococcus aureus Significant human pathogen. SSTI Biomaterial related infections Osteomyelitis Endocarditis Toxin mediated diseases TSST Staphylococcal enterotoxins Quintessential Pathogen? Nizet
More informationStaphylococcus aureus
Staphylococcus aureus Significant human pathogen. SSTI Biomaterial related infections Osteomyelitis Endocarditis Toxin mediated diseases TSST Staphylococcal enterotoxins Quintessential Pathogen? Nizet
More informationBarriers to Intravenous Penicillin Use for Treatment of Nonmeningitis
JCM Accepts, published online ahead of print on 7 July 2010 J. Clin. Microbiol. doi:10.1128/jcm.01012-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationMARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS
MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL 10%, solution for injection for cattle and swine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Marbofloxacin...100.0
More informationCHAPTER 1 INTRODUCTION
1 CHAPTER 1 INTRODUCTION The Staphylococci are a group of Gram-positive bacteria, 14 species are known to cause human infections but the vast majority of infections are caused by only three of them. They
More informationManagement of Native Valve
Management of Native Valve Infective Endocarditis 2005 AHA 2015 Baddour LM, et al. Circulation. 2015;132(15):1435-86 2009 ESC 2015 Habib G, et al. Eur Heart J. 2015;36(44):3075-128 ESC 2015: Endocarditis
More informationInternational Journal of Pharma and Bio Sciences
Research Article Microbiology International Journal of Pharma and Bio Sciences ISSN 0975-6299 EFFECT OF TOPICAL RECOMBINANT LYSOSTAPHIN AGAINST METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION IN
More informationRandall Singer, DVM, MPVM, PhD
ANTIBIOTIC RESISTANCE Randall Singer, DVM, MPVM, PhD Associate Professor of Epidemiology Department of Veterinary and Biomedical Sciences University of Minnesota Overview How does resistance develop? What
More informationDiurnal variation in microfilaremia in cats experimentally infected with larvae of
Hayasaki et al., Page 1 Short Communication Diurnal variation in microfilaremia in cats experimentally infected with larvae of Dirofilaria immitis M. Hayasaki a,*, J. Okajima b, K.H. Song a, K. Shiramizu
More informationSUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NUFLOR 300 mg/ml solution for injection for cattle and sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationClinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: HIM*, Medicaid
Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: HIM*, Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationReducing Infections in Surgical Practice. Fred A Sweet, MD Rockford Spine Center Illinois, USA
Reducing Infections in Surgical Practice Fred A Sweet, MD Rockford Spine Center Illinois, USA Introduction: How bacteria get in The Host The Surgeon The Procedure The STAFF Skin PREP Prophylactic Antibiotics
More information2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time)
Key words I μ μ μ μ μ μ μ μ μ μ μ μ μ μ II Fig. 1. Microdilution plate. The dilution step of the antimicrobial agent is prepared in the -well microplate. Serial twofold dilution were prepared according
More informationGregory Steinkraus 1 *, Roger White 2 and Lawrence Friedrich 3
Journal of Antimicrobial Chemotherapy (2007) 60, 788 794 doi:10.1093/jac/dkm258 Advance Access publication 10 July 2007 Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA),
More information